The prevalence of harmful BRCA gene changes in the general population is about 0.2%–0.3% (or about 1 in 400). However, in certain populations that are geographically or culturally distinct, the prevalence of specific BRCA mutations—called founder mutations—is higher.

Los hombres con cambios hereditarios dañinos en un gen BRCA deben hablar con su proveedor de atención de la salud sobre las opciones de exámenes de detección.

Apr 15, 2024 · For women with inherited harmful changes in BRCA genes, MRI surveillance and salpingo-oophorectomy can modestly reduce their risk of dying from breast and ovarian cancer, results from two studies show.

The ARIEL-2 phase II study found that rucaparib was effective in the treatment of recurrent, high-grade, platinum-sensitive ovarian cancer in women with BRCA variants, but also in BRCA wild-type women with high genomic loss of heterozygosity (LOH), which is a …

As a result of NCI's investment, people with a family history of breast and ovarian cancer can use their BRCA test results to help make informed decisions about screening and potential risk-reducing treatment.

Jul 12, 2017 · An international team of researchers has published results from the first large prospective study of breast and ovarian cancer risk in women who carry inherited BRCA mutations. The BRCA1 and BRCA2 genes code for proteins that are critical for …

Mar 1, 2016 · Current Trends in BRCA Testing The presence of a harmful BRCA gene mutation can not only influence a patient’s treatment decisions but also have implications for a patient’s family members. So clinicians often encourage young women diagnosed with breast cancer to be tested for BRCA mutations.

Feb 14, 2025 · Researchers used CRISPR gene editing technology to determine whether over 6,000 variants of BRCA2 were likely to cause cancer.

Jun 26, 2019 · Cancer cells with BRCA mutations already have defective DNA repair mechanisms, which, studies have shown, make them especially sensitive to PARP inhibitors. …

Nov 11, 2011 · BRCA.exp.547.med.txt - Full Expression Data set consisting of 522 primary tumors, 3 metastatic tumors, and 22 tumor-adjacent normal samples. Data was median centered by genes.